Heidi Overton Must Keep Her Promise to the Pro-Life Movement

Dr. Heidi Overton has spent years telling Americans where she stands on abortion.

If she is entrusted with leadership at the Food and Drug Administration, the pro-life movement should expect her to act accordingly.

Overton has built an extensive, self-authored record defending life. She has argued that radical abortion policies do not “follow the science.” She has written that advances in medicine have strengthened the pro-life argument. She has defended protections for unborn children and called on Americans to “reject abortion radicalism.”

Those were important words.

Now they must mean something.

Few issues will provide a clearer test than abortion drugs. The FDA has enormous power over how drugs like mifepristone are regulated and how easily they can reach American homes. Pro-life Americans should expect Overton to use that authority to protect women and unborn children, not continue the steady march toward making abortion pills easier and easier to obtain.

That means, at an absolute minimum, stopping any effort to make abortion drugs available over the counter.

There should be nothing routine about a drug whose intended purpose is to end the life of an unborn child. Treating abortion pills like another product on a pharmacy shelf would represent a profound moral and regulatory failure. It would further separate abortion from meaningful medical supervision and move America closer to a system in which obtaining an abortion is deliberately made as casual and convenient as possible.

Overton knows these arguments because she has made them herself.

In her work on medication abortion, she advocated more restrictive mifepristone policy, including ending telemedicine prescribing and restoring in-person patient evaluations. She understood that removing safeguards in the name of “access” carries consequences.

She should stand by that conviction.

Overton also defended Mississippi’s 15-week abortion law and supported the post-Dobbs return of abortion policymaking to elected officials. In a 2022 op-ed, she argued that technological and medical progress had strengthened the case for life and condemned abortion policies she believed had become radically detached from both science and morality.

The pro-life movement took those arguments seriously.

We should take them seriously now.

For too long, pro-life voters have heard strong promises only to watch Washington institutions move relentlessly in the opposite direction. Republican administrations cannot campaign on protecting life while allowing the administrative state to quietly expand access to abortion.

Personnel matters because policy follows personnel.

If Overton leads the FDA, she will have an opportunity to demonstrate that the principles she articulated before holding power still guide her when she possesses it.

She should oppose over-the-counter abortion drugs. She should revisit the loosening of safeguards surrounding mifepristone. She should restore meaningful medical oversight. And she should ensure that political pressure from the abortion industry never substitutes for serious scrutiny at the FDA.

The pro-life movement is not asking Overton to become someone different.

We are asking her to remain the person her own writings told us she was.

She told America that science strengthens the argument for life. She warned against abortion radicalism. She argued for greater safeguards around abortion drugs.

If given the power to do something about it, she must follow through.

For pro-life Americans, that is not an unreasonable expectation.

It is the promise her own record made.

Editor’s Note: Do you enjoy Townhall’s conservative reporting that takes on the radical Left and woke media? Support our work so that we can continue to bring you the truth.

Join Townhall VIP and use promo code FIGHT to receive 60% off your membership.